Biogen Braces For Cost Cuts As Business Transition Continues
Executive Summary
The company announced a new $1bn cost savings program that will result in 1,000 job cuts; $300m of the savings will be reinvested in new drug launches and R&D.
Topics
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC148759
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC148759
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.